Beyond PD-L1 Markers for Lung Cancer Immunotherapy.

Authors:
Kamila Wojas-Krawczyk
Kamila Wojas-Krawczyk
Medical University of Lublin
Poland
Ewa Kalinka
Ewa Kalinka
Medical University of Lodz
Poland
Janusz Milanowski
Janusz Milanowski
Medical University of Lublin
Poland

Int J Mol Sci 2019 Apr 18;20(8). Epub 2019 Apr 18.

Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.

Immunotherapy using immune checkpoints inhibitors has become the standard treatment for first and second line therapy in patients with non-small cell lung cancer (NSCLC). However, proper predictive factors allowing precise qualification of NSCLC patients for immunotherapy have not been developed so far. Expression of PD-L1 on tumor cells and tumor mutation burden are used in qualification of patients to first line therapy with pembrolizumab and atezolizumab in combination with ipilimumab in prospective clinical trials. Nevertheless, not all patients with these predictive factors benefit from immunotherapy. Major methodological difficulties in testing of these factors and in the interpretation of test results still exist. Therefore, other predictive factors are sought. Intensive research on the recognition of tumor immunophenotype and gut microbiome in NSCLC patients are underway. The first correlations between the effectiveness of immunotherapy and the intensity of inflammatory response in the tumor, microbiome diversity, and the occurrence of certain bacterial species in gut have been described. The purpose of our manuscript is to draw attention to factors affecting the efficacy of immunotherapy with anti-PD-L1 antibodies in NSCLC patients. Additional markers, for example TMB (tumor mutations burden) or microbiome profile, are needed to more accurately determine which patients will benefit from immunotherapy treatment.

Download full-text PDF

Source
https://www.mdpi.com/1422-0067/20/8/1915
Publisher Site
http://dx.doi.org/10.3390/ijms20081915DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515086PMC
April 2019
4 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter:
April 21, 2019, 3:07 am EST

Publication Analysis

Top Keywords

nsclc patients
12
predictive factors
12
benefit immunotherapy
8
lung cancer
8
immunotherapy
7
patients
7
tumor
5
factors
5
microbiome nsclc
4
gut microbiome
4
tumor immunophenotype
4
patients underway
4
immunophenotype gut
4
immunotherapy intensity
4
inflammatory response
4
response tumor
4
intensity inflammatory
4
effectiveness immunotherapy
4
correlations effectiveness
4
underway correlations
4

References

(Supplied by CrossRef)
Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)
Rizvi et al.
J. Clin. Oncol. 2015

Similar Publications